Biogen sues to fend off generic competition to MS drug Tecfidera

Biopharmalex 2021-06-16 11:26 am By Cat Fredenburgh | Melbourne

Please login to bookmark

Switzerland-based Biogen has sued generic drug maker MSN Laboratories for allegedly threatening to infringe the patent for its top-selling oral MS drug Tecfidera.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au